Tsuyoshi Kondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tsuyoshi Kondo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Akihito Suzuki
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036-8562, Japan
3 shared publicationsSunao Kaneko
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036-8562, Japan
3 shared publicationsKazuo Mihara
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036-8562, Japan
2 shared publicationsKoichi Otani
Department of Neuropsychiatry, Yamagata University School of Medicine, Yamagata 990-9585, Japan
2 shared publicationsNorio Yasui-Furukori
Department of Clinical Pharmacology, Hirosaki University Hospital, Hirosaki 036-8562, Japan
2 shared publicationsShingo Ono
Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki 036-8562, Japan
2 shared publications
Latest Publications
- 31 July 2002
- Published by Elsevier in International Congress Series
- Vol. 1244, 111-118
Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs
- 31 July 2002
- Published by Elsevier in International Congress Series
- Vol. 1244, 111-118
Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs
- 15 March 2002
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 26 (3) , 575-578
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients
- 15 March 2002
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 26 (3) , 575-578
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients
- Open Access
- 1 March 2002
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 90 (3) , 135-138
Altered Pharmacokinetics and Metabolism of Valproate after Replacement of Conventional Valproate with the Slow‐Release Formulation in Epileptic Patients
Altered metabolism of valproate has been suggested as the mechanism of teratogenicity and hepatotoxicity of valproate. This study aimed at examining whether pharmacokinetics of a slow‐release formulation of valproate affects valproate metabolism. Thirty‐one epileptic patients were treated with fixed‐doses of conventional valproate for at least 2 months. Thereafter, the drug was replaced with the same doses of slow‐release formulation of valproate for 2 months. Blood samplings for determination of valproate and its metabolites by gas chromatography‐mass spectrometry were performed at three time‐points (just before morning dose and at 1 and 5 hr after morning dose) during both treatment phases. There was a significant difference (P<0.005) in the mean serum concentration (±S.D.) of valproate after 1 hr between conventional valproate (63.1±27.9 μg/ml) and slow‐release formulation of valproate (45.7±19.5 μg/ml). Mean serum concentrations (±S.D.) of 4‐en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow‐release formulation of valproate (4‐en: 29.5±14.0→23.0±15.3 ng/ml, 3‐OH: 488.5±234.0→419.6±171.1 ng/ml, 4‐OH: 404.3±124.7→342.8±147.6 ng/ml, 5‐OH: 102.8±54.4→81.0±43.6 ng/ml). The present study suggests that smaller diurnal fluctuations in valproate concentrations during treatment with slow‐release formulation of valproate result in decreased formations of minor metabolites including 4‐en, the most toxic metabolite.
- 1 March 2002
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 90 (3) , 135-138
Open AccessAltered Pharmacokinetics and Metabolism of Valproate after Replacement of Conventional Valproate with the Slow‐Release Formulation in Epileptic Patients
Altered metabolism of valproate has been suggested as the mechanism of teratogenicity and hepatotoxicity of valproate. This study aimed at examining whether pharmacokinetics of a slow‐release formulation of valproate affects valproate metabolism. Thirty‐one epileptic patients were treated with fixed‐doses of conventional valproate for at least 2 months. Thereafter, the drug was replaced with the same doses of slow‐release formulation of valproate for 2 months. Blood samplings for determination of valproate and its metabolites by gas chromatography‐mass spectrometry were performed at three time‐points (just before morning dose and at 1 and 5 hr after morning dose) during both treatment phases. There was a significant difference (P<0.005) in the mean serum concentration (±S.D.) of valproate after 1 hr between conventional valproate (63.1±27.9 μg/ml) and slow‐release formulation of valproate (45.7±19.5 μg/ml). Mean serum concentrations (±S.D.) of 4‐en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow‐release formulation of valproate (4‐en: 29.5±14.0→23.0±15.3 ng/ml, 3‐OH: 488.5±234.0→419.6±171.1 ng/ml, 4‐OH: 404.3±124.7→342.8±147.6 ng/ml, 5‐OH: 102.8±54.4→81.0±43.6 ng/ml). The present study suggests that smaller diurnal fluctuations in valproate concentrations during treatment with slow‐release formulation of valproate result in decreased formations of minor metabolites including 4‐en, the most toxic metabolite.
- 18 May 2001
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 251 (2) , 57-59
Association between Taq I A dopamine D 2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report
The relationship between TaqI A dopamine D2 receptor (DRD2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6–18 mg/day for 3 weeks. Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The TaqI A genotypes were determined with the PCR method. There was no significant difference in the percentage improvement of total BPRS or 5-subgrouped symptoms (positive, negative, anxiety-depression, excitement and cognitive symptoms) after the 3-week treatment between the patients with A1 alleles (n=18) and those with no A1 allele (n=12). Although the present study is preliminary, it is suggested that the TaqI A DRD2 polymorphism is not associated with therapeutic response to bromperidol in schizophrenic patients.
- 18 May 2001
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 251 (2) , 57-59
Association between Taq I A dopamine D 2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report
The relationship between TaqI A dopamine D2 receptor (DRD2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6–18 mg/day for 3 weeks. Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The TaqI A genotypes were determined with the PCR method. There was no significant difference in the percentage improvement of total BPRS or 5-subgrouped symptoms (positive, negative, anxiety-depression, excitement and cognitive symptoms) after the 3-week treatment between the patients with A1 alleles (n=18) and those with no A1 allele (n=12). Although the present study is preliminary, it is suggested that the TaqI A DRD2 polymorphism is not associated with therapeutic response to bromperidol in schizophrenic patients.